TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12494299
Drug: Yoghurt (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoghurt (450 g for 4 months)
Study: 12494299
Drug: Partially skimmed
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partially skimmed milk (450 g for 4 months)
Study: 7731155
Drug: Ionic contrast
Normalized name: IONIC CONTRAST MEDIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ionic contrast agent (meglumine/sodium diatrizoate)
Study: 7731155
Drug: Ionic contrast
Normalized name: IONIC CONTRAST MEDIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ionic contrast agent (meglumine/sodium diatrizoate) with RI
Study: 7731155
Drug: Nonionic contrast
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonionic contrast agent (iohexol) with RI
Study: 6626426
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg pinacidil (single oral dose)
Study: 6626426
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg pinacidil (mean dose, twice daily for 3‐7 weeks)
Study: 6626426
Drug: Pinacidil (chronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinacidil (chronic treatment)
Study: 30179656
Drug: Piperacillin–tazobactam 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin–tazobactam 4 g/0.5 g at the time of intubation and 12 h later
Study: 26181769
Drug: Screening group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screening group (measuring thyroid function and thyroid antibody in early pregnancy)
Study: 26181769
Drug: Thyroid hormone
Normalized name: Thyroid hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroid hormone replacement therapy (for 105 SCH and 4 hypothyroid women in screening group)
Study: 26181769
Drug: Regular follow‐up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular follow‐up visits (for women in screening group who did not take medicine)
Study: 21947137
Drug: Risedronate 35
Normalized name: risedronate 35 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 35 mg delayed-release (DR) weekly (either before or after breakfast)
Study: 23079690
Drug: Risedronate 5
Normalized name: risedronate 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 5 mg immediate-release (IR) daily
Study: 19942104
Drug: Autologous blood
Normalized name: Banked autologous blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous blood therapy (ABT) - gluteal intramuscular reinjection of venous blood three times a week
Study: 19942104
Drug: Placebo -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - sterile sodium chloride solution
Study: 12174785
Drug: 15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg quinine twice a day for 3 days (group 1)
Study: 12174785
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg quinine twice a day for 3 days followed by a total dose of 25 mg chloroquine base over 3 days (group 2)
Study: 12174785
Drug: 50 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/kg chloroquine base given in 2 daily doses for 3 days (group 3)
Study: 9844152
Drug: Bicarbonate-buffered peritoneal
Normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicarbonate-buffered peritoneal dialysis solution (34 mmol/liter)
Study: 9844152
Drug: Lactate-buffered peritoneal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactate-buffered peritoneal dialysis solution (35 mmol/liter)
Study: 7813599
Drug: Roxindole 1
Normalized name: 3,3-Bis(4-hydroxyphenyl)oxindole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxindole 1 mg
Study: 851140
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 10 per cent ethanol
Study: 851140
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of ritodrine for 12 hours followed by oral ritodrine
Study: 16946657
Drug: Bupivacaine and
Normalized name: bupivacaine and meloxicam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine and methylprednisolone (30 mL 0.25% bupivacaine and 40 mg methylprednisolone) before wound closure
Study: 16946657
Drug: Bupivacaine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine alone (30 mL 0.25% bupivacaine) before closure
Study: 16946657
Drug: Bupivacaine and
Normalized name: bupivacaine and meloxicam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine and methylprednisolone (30 mL 0.25% bupivacaine and 40 mg methylprednisolone) before incision
Study: 16946657
Drug: Bupivacaine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine alone (30 mL 0.25% bupivacaine) before incision
Study: 16946657
Drug: Control (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (30 mL 0.9% NaCl before wound closure)
Study: 12880362
Drug: 1450-nm laser
Normalized name: aminosalicylic acid
DrugBank: Aminosalicylic acid (DB00233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1450-nm laser treatment with dynamic cooling
Study: 10875487
Drug: Clarithromycin 200
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin 200 mg twice daily for 8 weeks
Study: 9180600
Drug: 40 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/kg in one oral dose
Study: 9180600
Drug: two oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: two oral doses of 30 mg/kg at a 6-hr interval
Study: 8257124
Drug: Ultramicrosize griseofulvin
Normalized name: Ultramicrosize Griseofulvin Tablets
DrugBank: Griseofulvin (DB00400)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultramicrosize griseofulvin (UMSG) at 660 mg/day
Study: 8257124
Drug: Ultramicrosize griseofulvin
Normalized name: Ultramicrosize Griseofulvin Tablets
DrugBank: Griseofulvin (DB00400)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultramicrosize griseofulvin (UMSG) at 990 mg/day
Study: 8257124
Drug: Itraconazole at
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole at 100 mg/day
Study: 27614001
Drug: Mycophenolate treatment
Normalized name: mycophenolate
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mycophenolate treatment
Study: 23755093
Drug: Oxygen supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen supplementation at 2 or 3 L/min for 72 hours
Study: 23755093
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (room air)
Study: 15882228
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml erythrosine mouthwash for 15 s rinsing period
Study: 15882228
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml erythrosine mouthwash for 30 s rinsing period
Study: 15882228
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml erythrosine mouthwash for 60 s rinsing period
Study: 15882228
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml erythrosine mouthwash for 90 s rinsing period
Study: 10475181
Drug: Non-invasive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-invasive treatment strategy
Study: 8732321
Drug: Results of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Results of a self‐administered computerized assessment (PROQSY) of common mental disorders provided to the GP
Study: 1890863
Drug: Autologous bone
Normalized name: Human autologous bone marrow derived osteoblastic cells
DrugBank: Human autologous bone marrow derived osteoblastic cells (DB18259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous bone marrow transplantation following high dose chemotherapy and radiation therapy (RT)
Study: 1890863
Drug: RT followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT followed by adjuvant chemotherapy
Study: 6579843
Drug: Budesonide (intranasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (intranasal corticosteroid)
Study: 30556961
Drug: Topical 0.1%
Normalized name: adapalene topical 0.1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.1% triamcinolone (TA) preparation
Study: 30556961
Drug: Topical 0.2%
Normalized name: coal tar topical 0.2% topical soap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.2% hyaluronic acid (HA) preparation
Study: 27825036
Drug: S-MAPS (Standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-MAPS (Standard MAPS treatment)
Study: 25369831
Drug: Rimostil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimostil (50 mg)
Study: 20371736
Drug: Linezolid and
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Linezolid and rifampin (combination)
Study: 16937509
Drug: Routine non-operative
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine non-operative conservative treatments (group 2)
Study: 14618331
Drug: Concurrent weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent weight training during FES cycle ergometry three times per week
Study: 11737179
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no hypotensive agent)
Study: 3591681
Drug: Pindolol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (mean dose 17 +/- 8 mg/day)
Study: 3591681
Drug: Propranolol (130
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (130 +/- 40 mg/day)
Study: 27442394
Drug: GA +
Normalized name: Sea-Omega + D Softgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: GA + TAP-D block with 25 ml of 0.5% ropivacaine + 4 mg Dexamethasone
Study: 27442394
Drug: GA +
Normalized name: Sea-Omega + D Softgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: GA + TAP block with 25 ml of 0.5% ropivacaine
Study: 15452808
Drug: Guided-tissue regeneration
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided-tissue regeneration therapy (GTR therapy)
Study: 23204168
Drug: FMP2.1/AS02(A) malaria
Approvals — FDA: no, EMA: no, PMDA: no
Description: FMP2.1/AS02(A) malaria vaccine
Study: 19694381
Drug: Tamsulosin (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin (0.2 mg once a day)
Study: 19694381
Drug: Tamsulosin (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin (0.2 mg once a day) + Tolterodine (2 mg twice a day)
Study: 16476220
Drug: Long-term insulin
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term insulin treatment
Study: 15470173
Drug: Desflurane 1
Normalized name: desflurane 1000 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desflurane 1 MAC, administered 30 min prior to the end of the surgical procedure.
Study: 11304776
Drug: Epirubicin (110
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin (110 mg/m²) followed by paclitaxel (225 mg/m²) every 2 weeks for four cycles each, with granulocyte colony-stimulating factor support (Group A)
Study: 11304776
Drug: Epirubicin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin (80 mg/m²) followed by paclitaxel (175 mg/m²) every 3 weeks for six cycles (Group B)
Study: 7506170
Drug: diclofenac (50mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: diclofenac (50mg twice daily)
Study: 3318259
Drug: Insulin +
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin + glipizide (3 X 10 mg/day)
Study: 19047916
Drug: Prenatal drug
Normalized name: Ardisia crenata root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenatal drug exposure (PDE) children remaining in maternal care
Study: 19047916
Drug: Prenatal drug
Normalized name: Ardisia crenata root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenatal drug exposure (PDE) children in nonmaternal care
Study: 19047916
Drug: Community comparison
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community comparison (CC) children
Study: 14578832
Drug: High-dose midazolam
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose midazolam (1 mg/kg, HDM)
Study: 14578832
Drug: Standard-dose midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard-dose midazolam (0.5 mg/kg, SDM)
Study: 6570116
Drug: Cefoxitin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin (2 g) intravenously at the time of induction of anaesthesia
Study: 6570116
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group without the antibiotic
Study: 30205746
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg BMS-986165 every other day
Study: 30205746
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg BMS-986165 daily
Study: 30205746
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg BMS-986165 twice daily
Study: 30205746
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg BMS-986165 twice daily
Study: 30205746
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg BMS-986165 daily
Study: 27454263
Drug: Hydromorphone 0.25
Normalized name: HYDROMORPHONE 0.25MG/0.5ML INJ 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone 0.25 mg
Study: 27454263
Drug: Ibuprofen 25
Normalized name: ibuprofen 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 25 mg + Hydromorphone 0.125 mg
Study: 27454263
Drug: Ibuprofen and
Normalized name: Ibuprofen and Famotidine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen and Hydromorphone combination
Study: 21194605
Drug: Levetiracetam 250
Normalized name: levetiracetam 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam 250 mg administered as an immediate-release tablet
Study: 17497175
Drug: COMT Ex4‐76C
Approvals — FDA: no, EMA: no, PMDA: no
Description: COMT Ex4‐76C > G (Leu136Leu) polymorphism
Study: 17497175
Drug: COMT haplotypes
Normalized name: levodopa, decarboxylase inhibitor and COMT inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: COMT haplotypes including variant allele for COMT Ex4‐76 C > G
Study: 12118903
Drug: Darusentan 30
Normalized name: Darusentan
DrugBank: Darusentan (DB04883)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darusentan 30 mg
Study: 8201928
Drug: Norfloxacin 800
Normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norfloxacin 800 mg daily or Ciprofloxacin 1000 mg daily
Study: 3493903
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose MTX (regimen I)
Study: 3493903
Drug: Moderate dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate dose MTX (regimen II)
Study: 3493903
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (both regimens)
Study: 27733165
Drug: ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ibuprofen 400 mg PO and metoclopramide 10 mg PO
Study: 27733165
Drug: tramadol 50
Normalized name: traMADol 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: tramadol 50 mg PO
Study: 27733165
Drug: placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (two placebo pills)
Study: 23558663
Drug: Radiographic assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiographic assessment of femoral implant position
Study: 16729918
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (CBT) in addition to mebeverine hydrochloride
Study: 10992533
Drug: Fluticasone aqueous
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone aqueous spray 200 microgram once daily (first season)
Study: 10992533
Drug: Beclomethasone 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone 200 microgram twice daily (second season)
Study: 8792038
Drug: Oral magnesium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral magnesium 600 mg (24 mmol) daily for 12 weeks
Study: 1377035
Drug: High-dose aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose aprotinin (GpI)
Study: 23399046
Drug: Machined implant
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Machined implant neck design
Study: 23399046
Drug: Anodized implant
Normalized name: calcium iodized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anodized implant neck design
Study: 22827973
Drug: Polyphenon E
Normalized name: Polyphenon E
DrugBank: Sinecatechins (DB01266)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polyphenon E (Poly E) 400 mg twice daily
Study: 22827973
Drug: Polyphenon E
Normalized name: Polyphenon E
DrugBank: Sinecatechins (DB01266)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polyphenon E (Poly E) 600 mg twice daily
Study: 22827973
Drug: Polyphenon E
Normalized name: Polyphenon E
DrugBank: Sinecatechins (DB01266)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polyphenon E (Poly E) 800 mg twice daily
Study: 20845296
Drug: L‐carnitine 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐carnitine 25 mg/day
Study: 16200756
Drug: EMG-triggered robot-assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMG-triggered robot-assisted therapy
Study: 14571302
Drug: Ezetimibe (cholesterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe (cholesterol absorption inhibitor)
Study: 14571302
Drug: Ezetimibe in
Normalized name: Product containing ezetimibe in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe in combination with atorvastatin or simvastatin
Study: 10770363
Drug: Nandrolone decanoate
Normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nandrolone decanoate (50 mg, 5 injections over 3 months)
Study: 10770363
Drug: Placebo (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5 injections over 3 months)
Study: 8901790
Drug: Diet containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet containing 300 g shrimp/d (590 mg dietary cholesterol/d)
Study: 8901790
Drug: Diet containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet containing two large eggs per day (581 mg dietary cholesterol/d)
Study: 2126147
Drug: Ranitidine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (2 x 150 mg)
Study: 1829300
Drug: Sucralfate (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (4 x 1 g)
Study: 1829300
Drug: Indomethacin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (2 x 50 mg for 3 weeks)
Study: 30739941
Drug: Subcostal TAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcostal TAP block with 10 mL of 0.25% bupivacaine
Study: 30369310
Drug: Levosimendan (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan (loading dose 12 μg/kg + 0.1 μg/kg per minute)
Study: 30369310
Drug: Dobutamine (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine (7.5 μg/kg per minute)
Study: 21228025
Drug: subcutaneous interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous interferon beta-1a (44 mcg three times weekly)
Study: 21228025
Drug: intramuscular interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intramuscular interferon beta-1a (30 mcg weekly)
Study: 21228025
Drug: glatiramer acetate
Normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: glatiramer acetate (20 mg daily)
Study: 20819471
Drug: Amoxicillin/clavulanate for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate for 2 weeks after ESS
Study: 16428941
Drug: Metopimazine (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metopimazine (7.5 mg x 2 t.i.d.)
Study: 16428941
Drug: Ondansetron (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (8 mg b.i.d.)
Study: 29026170
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose AN-PEP
Study: 29026170
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose AN-PEP
Study: 21898717
Drug: Augmentation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmentation with buspirone
Study: 11777630
Drug: Tailored chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored chemotherapy (FEC: cyclophosphamide, epirubicin, 5‐fluorouracil)
Study: 11777630
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy (CTCb: cyclophosphamide, thiotepa, carboplatin)
Study: 10728155
Drug: Body weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Body weight treatment
Study: 10728155
Drug: Body fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Body fat treatment (measured by anthropometrics)
Study: 8083704
Drug: Weekly chemotherapy
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly chemotherapy (12 alternating cycles of ifosfamide/doxorubicin and cis-platin/etoposide)
Study: 8083704
Drug: 3-week chemotherapy
Normalized name: etonogestrel
DrugBank: Etonogestrel (DB00294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-week chemotherapy (6 alternating cycles of cyclophosphamide/doxorubicin/vincristine and PE)
Study: 8083704
Drug: Weekly chemotherapy
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly chemotherapy
Study: 8083704
Drug: 3-week chemotherapy
Normalized name: etonogestrel
DrugBank: Etonogestrel (DB00294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-week chemotherapy
Study: 2670465
Drug: Ciprofloxacin (IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (IV 200 to 300 mg twice daily, followed by oral 500 mg twice daily)
Study: 2670465
Drug: Ceftazidime (IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime (IV 1 to 2 g two to three times daily)
Study: 59850
Drug: Bromocriptine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (mean daily dose 79 mg)
Study: 25528557
Drug: Portrayals of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Portrayals of successfully treated schizophrenia, prescription painkiller addiction, and heroin addiction